Voyager Therapeutics, Inc.

What they do

Voyager Therapeutics is a biotechnology company focused on developing genetic medicines for neurological diseases, leveraging its TRACER AAV capsid discovery platform and NeuroShuttle non-viral platform. Its wholly-owned pipeline prioritizes two tau-targeting Alzheimer's disease programs: VY1706, a tau silencing gene therapy, and VY7523, an anti-tau antibody. The company also advances partnered programs with Neurocrine (Friedreich's ataxia and GBA1 gene therapy) and Transition Bio (small molecules for ALS/FTD), with opt-in rights for co-development/commercialization. It derives revenue primarily from collaboration and licensing agreements with partners such as Alexion, Novartis, and Neurocrine.

Revenue drivers

• Neurocrine collaboration — Recognized $3.2 million in collaboration revenue in Q2 2026, down from $5.2 million in Q2 2025 as activities transition beyond the research phase; includes opt-in rights for FA and GBA1 programs.
• Other collaboration and licensing agreements — Includes agreements with Alexion, Novartis, and Transition Bio; these agreements typically provide upfront and milestone payments that drive revenue variability, as seen in the $250 million spike in 2023.
• Collaboration revenue overall — Total collaboration revenue was $40.4 million in 2025, down from $80.0 million in 2024 and the $250.0 million peak in 2023, reflecting the stage and timing of partner activities.

Recent performance

For Q2 2026, Voyager reported collaboration revenue of $3.2 million (down from $5.2 million in Q2 2025), R&D expenses of $22.0 million, G&A expenses of $7.5 million, and a net loss of $24.5 million (improved from a net loss of $33.4 million in Q2 2025). Cash, cash equivalents, and marketable securities were $148.8 million as of June 30, 2026. The company ended Q2 2026 with total assets of $197.8 million and shareholder equity of $154.4 million, and has an accumulated deficit of $445.9 million as of December 31, 2025.

Strategy

Voyager is prioritizing its wholly-owned Alzheimer's disease pipeline, focusing on tau as a disease-modifying target and advancing two tau-targeted programs toward clinical milestones. The company expects to begin dosing VY1706 in Q4 2026 and to report tau PET imaging data from VY7523 in Q4 2026. Management has paused investment in its APOE gene therapy program to prioritize other programs and has implemented restructuring actions to reduce expenses. The company also retains opt-in rights in partnered programs with Neurocrine and Transition Bio to participate in future development and commercialization, and continues to advance its TRACER and NeuroShuttle platforms.

Risks

• Clinical development risk — VY1706 and VY7523 are in early-stage development and may fail to demonstrate safety or efficacy; VY1706 has not yet begun dosing.
• Cash runway and funding risk — With a net loss of $119.7 million in 2025 and cash of $148.8 million as of June 30, 2026, the company has runway into 2028 but may need additional capital to fund operations and complete clinical trials.
• Dependence on collaboration partners — Voyager's revenue and future development of partnered programs rely on collaborations with Neurocrine, Novartis, Alexion, and Transition Bio; partner decisions could affect milestones and opt-in opportunities.
• Regulatory and manufacturing risk — The company's gene therapy programs depend on FDA and other regulatory approvals, and manufacturing of AAV-based products is complex and subject to delays or failure.

Outlook

Management expects to begin dosing VY1706 in adults with early Alzheimer's disease in Q4 2026, with initial acute safety data potentially in early 2027 and biomarker-based data in H2 2027, pending enrollment. VY7523 tau PET imaging data are expected in Q4 2026. Neurocrine intends to initiate a clinical trial with NBIB-'223 for Friedreich's ataxia in H2 2026, pending FDA IND clearance. Cash is projected to fund operations into 2028.